中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Fat Mass Estimation in Overweight and Obesity

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
University of Roma La Sapienza

关键词

抽象

The prevalence of individuals who are classified as overweight or obese is increasing all over the world and it represents a primary health concern due to the relationship between obesity and a number of diseases, disabilities, comorbidities, and mortality. The definition of obesity should consider not only the increase of body weight but more precisely the increase in body fat mass. However, body composition evaluation is rarely performed in overweight and obese subjects and the diagnosis is almost always achieved just considering body mass index (BMI). In fact, whereas BMI can be considered an important tool in epidemiological surveys, different papers stated the limitations of the use of BMI in single individuals.
Aim: to assess the determinants of body composition in a population of overweight and obese subjects and to propose a different model of estimation of fat mass (FM) in these subjects when more reliable equipments for the evaluation of body composition are not available.
Methods: in 103 overweight or obese subjects ( 74 women, aged 41.5±10 years, and 29 men, aged 43.8±8 years); a multidimensional evaluation was performed including the assessment of body composition using Dual Energy X-Ray Absorptiometry (DXA), anthropometry, bioimpedance analysis (BIA) and biochemical parameters (total cholesterol, triacylglycerol, HDL- and LDL- cholesterol, free fatty acids and glycerol, glucose, insulin, C-reactive protein, plasma acylated and unacetylated ghrelin, adiponectin and leptin serum levels).

描述

Participants This study was based on the baseline data from a randomised controlled trial aimed at the evaluation of the effects of 2- month consumption of a combination of bioactive food ingredients on changes in body composition, satiety control, thermogenesis, serum markers of lipolysis .

The study was performed under the approval of the Ethics Committee of the Department of Internal Medicine and Medical Therapy at University of Pavia. The informed consent to the study was obtained by all the participants or their legal representatives. Healthy males and females aged from 25 to 45 years, with a BMI greater than 25 kg/m2 and less than 35 kg/m2, were eligible for the study. All subjects underwent physical examination, anthropometric assessment and routine laboratory tests. The complete medical history was collected for all the subjects. Individuals who were pregnant or lactating, or had any disease potentially affecting body composition and laboratory evaluation were excluded from the study, especially severe hepatic or renal disease, unstable cardiovascular disease, uncontrolled hypertension, active cancer or surgery for weight loss were the main exclusion criteria.

Multidimensional evaluation After a 12- hour fasting, and abstinence from water since midnight, the subjects arrived at around 8:00 a.m., using motorised transportation, at the Endocrinology and Clinical Nutrition Unit of the University of Pavia (Italy) and at the Dietetic and Metabolic Unit, "Villa delle Querce" Clinical Rehabilitation Institute in Rome (Italy).

Blood sampling for routine blood analysis and for the measurements of leptin, adiponectin, ghrelin, insulin, glycerol, free fatty acid levels, as well as the assessment of body composition by dual energy X-ray absorptiometry (DXA) and anthropometry were performed in the fasting state at baseline.

Body composition was measured using DXA (Lunar Prodigy DXA, General Electric Medical Systems, Wisconsin). The in vivo coefficients of variation were 4.2% and 0.48% for fat and lean mass, respectively. Central fat, defined as the approximation of the visceral fat, was assessed with DXA, measuring the fat percentage corresponding to an ideal rectangle defined from the upper edge of the second lumbar vertebra to the lower edge of the fourth lumbar vertebra. The vertical sides of this area were the continuation of the lateral sides of the rib cage . All measurements for each parameter were gathered by the same investigator.

The following anthropometric measurements were performed in all subjects:

body weight and height; biceps (BSF), triceps (TSF), suprailiac (SISF), and subscapular (SSSF) skinfold thicknesses, waist circumference (W), hip circumference (H), arm circumference (AC) and calf circumference (CC) In order to avoid the inter- assessor variability, anthropometric variables were measured by a unique investigator following a standardized technique .

Using the abovementioned anthropometric parameters, the following variables were calculated:

Body mass index (BMI): weight (kg) / height2 (m2) Waist to hip ratio (WHR) arm muscle area arm fat area muscle arm circumference Bioimpedance analysis (BIA): whole-body impedance vector components, resistance (R) and reactance (Xc), were measured with a single-frequency 50- KHz analyzer from AKERN Bioresearch Italy). Measurements were obtained following standardized procedures . The external calibration of the instrument was checked with a calibration circuit of known impedance value. Estimations of fat-free mass (FFM) and FM by BIA were obtained using gender- specific, BIA prediction equations recently developed by Sun et al in a large population that included extremes of BMI values. The fat mass index (FMI) was calculated through the normalisation of FM, obtained by the BIA, for height: FMI = FM (kg)/ height (m)2.

Biochemical analyses

Subjects were instructed to fast over 12 hours, and to refrain from any form of exercise for 48 hours, before blood collection. Female subjects were tested during the early follicular phase of their menstrual cycles (days 3-10). Fasting venous blood samples were drawn between 08.00 and 10.00 a.m.. Blood collection and handling were carried out under strictly standardized conditions and clinical chemistry parameters were detected with dedicated commercial kits. In particular total cholesterol, triacylglycerol, HDL- and LDL- cholesterol, free fatty acid (FFA), glycerol, glucose, insulin, C- reactive protein (CRP), plasma acylated and unacetylated ghrelin, adiponectin and leptin serum levels were measured. Leptin/ adiponectin ratio (LAR) was calculated. Insulin resistance was evaluated using the Homeostasis Model Assessment (HOMA) and Quantitative Insulin sensitivity Check Index (QUICKI) using the following formulas:

HOMA-Insulin Resistance = [(fasting insulin, mcU/ml) x (plasma glucose, mmol/l)]/22.5 QUICKI = 1/ [log (glucose, mg/dl) + log (insulin, µU/ml)] Statistical analysis Data were described as mean and standard deviation (SD) if continuous and as percentage if categorical.

We considered FM from DXA as the outcome variable and all the anthropometric, bioimpedance and laboratory data as potential explicative variables.

The predictive value of BMI and FM from BIA were compared to the FM from DXA (overall predictive value, sensibility, specificity, positive and negative predictive values). Therefore we considered the following cut-off values for the definition of obesity :

FM ≥ 25 % for men and ≥ 35 % for women (at DXA and BIA) BMI ≥ 30 kg/m2 6 The variance analysis and the Student t-test were used to assess the significance of differences in the averages; the χ2 to compare the frequencies observed with those expected; the Pearson's to evaluate the correlation existing between two continuous variables.

Variables univariately proven correlated with the outcome variable were entered a pool of potential contributors in multiple regression analysis.

We estimated models using a forward likelihood stepwise method (cut-off probability for entry: 0.05). With each added variable the discriminant function was recalculated and any variable that no longer met the significance level was removed from the equation (cut-off probability for removal: 0.1).

Some variables with similar biological significance were excluded from the logistic analysis, in order to avoid the confounding effect of collinearity (verified with Pearson's r, t-test or χ2). The best fitting model was chosen according to the value of the correlation coefficients R2, (comparing the explained variance of the model's predictions with the total variance of the data), the adjusted R2 (R2 adj), considering a correction for inclusion of variables.

We considered a significance level equal to a 5% probability of error. Data were analysed using the SPSS for Windows 10.0 (SPSS Inc 1989-1999) and the Win Episcope 2.0 [Wageningen University (N), University of Edinburgh (GB)] statistical software packages.

日期

最后验证: 02/28/2013
首次提交: 02/27/2013
提交的预估入学人数: 03/05/2013
首次发布: 03/06/2013
上次提交的更新: 03/05/2013
最近更新发布: 03/06/2013
实际学习开始日期: 02/28/2011
预计主要完成日期: 11/30/2011
预计完成日期: 11/30/2011

状况或疾病

Obesity

-

手臂组

干预/治疗
obese subjects
One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);

资格标准

有资格学习的年龄 20 Years 至 20 Years
有资格学习的性别All
取样方式Probability Sample
接受健康志愿者
标准

Inclusion Criteria:

- Healthy males and females aged from 25 to 45 years, with a BMI greater than 25 kg/m2 and less than 35 kg/m2, were eligible for the study.

Exclusion Criteria:

- No exclusion criteria

结果

主要结果指标

1. body composition [one month]

The purpose of this study is to verify the determinants of body composition in a population of overweight and obese subjects and to propose a different model of estimation of FM of these subjects when reliable equipments for the evaluation of body composition are not available. Body composition will be measured through anthropometry (skinfold thickness), bioimpedance analysis and DXA.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge